Monthly Archives: January 2013

Teva and Tire Irons: The Risk of Going MAD

(from NP February: this replaces a previous post on the Teva topic) Teva‘s CEO Jeremy Levin is understandably concerned about protecting Teva’s MS franchise drug, Copaxone, particularly since Teva/Active Biotech‘s oral MS entrant, laquinimod, has underperformed thus far, and must … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , , | 1 Comment

Pharma New Math: Harvard+MIT>Yale

The Pharma industry has no lack of leaders whose creative vision extends only to the backside of the company walking directly in front of them. Consider the latest corporate substitute for originality, the belief that location and proximity are the … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , | Leave a comment